^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATA3219

    i
    Other names: ATA3219
    Company:
    Atara
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    7ms
    ATA3219-AEC-104: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=0, Withdrawn, Atara Biotherapeutics | N=52 --> 0 | Trial completion date: Apr 2029 --> Apr 2025 | Initiation date: Nov 2024 --> Apr 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2027 --> Apr 2025
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    ATA3219
    7ms
    ATA3219-NHL-103: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=1, Terminated, Atara Biotherapeutics | N=40 --> 1 | Trial completion date: Nov 2028 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: May 2026 --> Mar 2025; Financial reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ATA3219
    12ms
    ATA3219-NHL-103: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Atara Biotherapeutics | Initiation date: Jan 2024 --> Sep 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    ATA3219
    over1year
    ATA3219-AEC-104: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Atara Biotherapeutics | N=26 --> 52
    Enrollment change • CAR T-Cell Therapy
    |
    ATA3219
    over1year
    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, Atara Biotherapeutics
    New P1 trial • CAR T-Cell Therapy
    |
    ATA3219
    almost2years
    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Atara Biotherapeutics
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    ATA3219
    almost3years
    Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy without Gene-Editing (TCT-ASTCT-CIBMTR 2023)
    This updated preclinical dataset for ATA3219 demonstrates the flexibility of our EBV T-cell manufacturing process through improvements in the polyfunctional phenotype, potent expansion and targeting against B cell tumors with low alloreactivity. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    ATA3219
    almost5years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost5years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost5years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost5years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost5years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219